Sponsor content
348 result(s) found, displaying 71 to 80
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Designation or determinationPriority review
-
Designation or determinationOrphan drug
-
Australian public assessment report (AusPar)WELIREG (belzutifan) is indicated for treatment of patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system haemangioblastomas, or pancreatic neuroendocrine tumours, not requiring immediate surgery.
-
Australian public assessment report (AusPar)Vaxneuvance, a vaccine, has been approved for the prevention of pneumococcal disease caused by Streptococcus pneumoniae.